eCite Digital Repository

Tobacco dependence and withdrawal: Science base, challenges and opportunities

Citation

Henningfield, JE and Shiffman, S and Ferguson, SG and Gritz, ER, Tobacco dependence and withdrawal: Science base, challenges and opportunities, Pharmacology and Therapeutics, 123, (1) pp. 1-16. ISSN 0163-7258 (2009) [Refereed Article]


Preview
PDF
Restricted - Request a copy
5Mb
  

Copyright Statement

The definitive version is available at http://www.sciencedirect.com

DOI: doi:10.1016/j.pharmthera.2009.03.011

Abstract

Several pharmacotherapies for tobacco dependence and withdrawal have been approved by the Food and Drug Administration to aid smoking cessation. These medicines double to triple the odds of cessation compared to placebo, with the diversity in chemical entity (e.g., nicotine, varenicline, bupropion) and route (e.g., nicotine gum and transdermal patch) providing options for people who find a given medication unacceptable or ineffective. Treatments in development include vaccines, combinations of existing products, and new indications, such as reduced tobacco use and exposure. These therapies have been developed on the foundation of research on the neuropharmacology of tobacco dependence and withdrawal. Ongoing research is expected to contribute to more efficacious use of existing therapies and the development of new approaches. This article addresses these developments as well as the challenges to medication development. Challenges include understanding the population-based and individual differences in the vulnerability to dependence and responsiveness to various treatment options, which could contribute to effective treatment to patient matching. Research on the CNS effects of administration and withdrawal of nicotine and other tobacco product constituents is expanding, providing the basis for more effective therapeutic approaches and new medications development. Additionally, whereas medications are approved on the basis of standardized assessments of efficacy and safety in clinical trials, the public health impact of medications depends also on their appeal to smokers and their effectiveness in actual use settings. Research on more effective medication use along with policies that support improved access and utilization are vital to conquering the tobacco epidemic.

Item Details

Item Type:Refereed Article
Keywords:tobacco; nicotine; treatment; drug; pharmacotherapy; mechanism; brain; nicotine replacement therapy; varenicline; bupropion; gum; patch; lozenge; inhaler; nasal; policy; efficacy; epidemiology; withdrawal; brain imaging; receptors
Research Division:Medical and Health Sciences
Research Group:Pharmacology and Pharmaceutical Sciences
Research Field:Clinical Pharmacy and Pharmacy Practice
Objective Division:Health
Objective Group:Public Health (excl. Specific Population Health)
Objective Field:Substance Abuse
Author:Ferguson, SG (Associate Professor Stuart Ferguson)
ID Code:57231
Year Published:2009
Web of Science® Times Cited:50
Deposited By:Pharmacy
Deposited On:2009-06-30
Last Modified:2014-12-17
Downloads:0

Repository Staff Only: item control page